pCDCAR1 HLA-A2-WT1Db126 h(BBFcγR1γ)(CAR-LC266)
The vector of anti-HLA-A2-WT1Db126 chimeric antigen receptor (CAR) is TCR-like CAR constructed for the engineering of T cells to target human HLA-A2-WT1Db126. The T cells are genetically modified through transduction with a retroviral vector expressing scFv of anti-HLA-A2-WT1Db126 antibody linked to CD28 signaling domain and FcγR1γ. And the vector product was designed for the treatment of breast carcinoma and colon cancer.
Targeting Cell Type
Breast carcinoma, Colon cancer
Discription of Signaling Cassetes
CD28 (Cluster of Differentiation 28) is one of the proteins expressed on T cells that provide co-stimulatory signals required for T cell activation and survival. CD28 is the receptor for CD80 (B7.1) and CD86 (B7.2) proteins which are expressed on antigen-presenting cells (APC). CD28 modulates the primary TCR/CD3ζ signal in a different fashion than the late costimulatory elements OX40 and 4-1BB. CD28 enhances the expression of downstream regulators that impact on T-cell proliferation, death, differentiation, and effector functions. CAR+ T cells containing the CD28 endodomain showed strikingly enhanced sustained T cell activation, growth, survival. And CD28 results in a brightly expressed, stable receptor as the transmembrane domain. Including CD28 costimulatory domains in CARs led to enhanced anti-malignancy efficacy.
HLA-A2-WT1Db126; HLA-A2-WT1Db126 complex
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.